Rabbit Recombinant Monoclonal TXNIP antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
May act as an oxidative stress mediator by inhibiting thioredoxin activity or by limiting its bioavailability (PubMed:17603038). Interacts with COPS5 and restores COPS5-induced suppression of CDKN1B stability, blocking the COPS5-mediated translocation of CDKN1B from the nucleus to the cytoplasm (By similarity). Functions as a transcriptional repressor, possibly by acting as a bridge molecule between transcription factors and corepressor complexes, and over-expression will induce G0/G1 cell cycle arrest (PubMed:12821938). Required for the maturation of natural killer cells (By similarity). Acts as a suppressor of tumor cell growth (PubMed:18541147). Inhibits the proteasomal degradation of DDIT4, and thereby contributes to the inhibition of the mammalian target of rapamycin complex 1 (mTORC1) (PubMed:21460850).
VDUP1, TXNIP, Thioredoxin-interacting protein, Thioredoxin-binding protein 2, Vitamin D3 up-regulated protein 1
Rabbit Recombinant Monoclonal TXNIP antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Expression levels of the target protein vary with sample type and some optimisation may be required. For western blotting, more concentrated lysates may be required when using tissues samples. Stimulation may be required to allow detection of the target protein due to low levels of endogenous expression in some samples. Please see images below for recommended treatment conditions and positive controls.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
TXNIP also known as thioredoxin-interacting protein or VDUP1 is an inhibitory protein that binds to and regulates the activity of thioredoxin. It has a molecular mass of around 46 kDa. TXNIP is expressed in various tissues including heart liver and skeletal muscle. It acts to control intracellular redox states by modulating thioredoxin’s antioxidant functions. TXNIP expression can vary according to oxidative stress and cellular metabolic conditions.
TXNIP regulates cellular processes such as glucose metabolism stress response and apoptosis. It does not form a complex but functions by negatively regulating the activity of thioredoxin. This protein can lead to increased reactive oxygen species (ROS) when it inhibits thioredoxin influencing cellular redox balance. TXNIP therefore plays a regulatory role in metabolic pathways and cellular stress responses by modulating thioredoxin activity and ROS levels.
TXNIP is a significant component of the oxidative stress and glucose metabolism pathways. In the oxidative stress pathway TXNIP interacts with thioredoxin influencing ROS detoxification and redox-sensitive signaling. In glucose metabolism TXNIP can affect insulin signaling by interacting with glucose transporter-1 (GLUT1). These interactions highlight TXNIP's regulatory role in cellular metabolism and stress-related signaling making it a node of convergence with proteins like thioredoxin and GLUT1.
TXNIP levels have been implicated in conditions such as type 2 diabetes and cardiovascular diseases. Elevated TXNIP expression has been observed in insulin resistance where it affects glucose uptake by modifying GLUT1 activity and links to thioredoxin in cardiovascular tissues resulting in oxidative stress damage. These connections position TXNIP as a potential therapeutic target for managing metabolic disorders and cardiovascular complications.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com